The United States Patent and Trademark Office (USPTO) has granted patent US12582685B2 to Fjord Biotech AS. This patent covers the use of sulphated heteropolymer polysaccharides obtained from the order Prasinococcales, specifically those with an average molecular weight between 1,000 and 40,000 kDa. The granted claims pertain to the application of these polysaccharides for treating skin irritation, wound repair, fibrotic conditions, keloid scarring, and viral infections, as well as their use as biological carriers, scaffolds, or bio-lubricants, including in antiviral compositions.

This patent grant signifies a new intellectual property right for Fjord Biotech AS in the field of pharmaceutical and biotechnological applications. While patents do not impose direct regulatory obligations on other entities, they establish exclusive rights that can impact market entry and product development for competitors. Companies operating in the wound repair, antiviral, or biomaterials space should be aware of this granted patent to ensure their own products and research do not infringe upon Fjord Biotech's exclusive rights. No immediate compliance actions are required for other entities, but strategic review of existing and future product pipelines is advisable.